Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

130
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
130
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

135
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
135
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

428
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
428
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.2K
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

2.6K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
2.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adult-onset nephroblastoma in a male patient: a case report.

AME case reports·2026
Same author

Reliability of Prostate Imaging-reporting and Data System Scoring Following Holmium Laser Enucleation of Prostate.

Urology·2025
Same author

Testicular vasal diameter: A new intra-operative predictor of vasectomy reversal success?

Andrology·2025
Same author

Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.

Urologic oncology·2023
Same author

Can Retroperitoneal Lymph Node Dissection (RPLND) be feasibly performed to prolong survival in Renal Cell Carcinoma (RCC) with limited lymph node involvement? An Analysis of Recurrence Patterns.

Urologic oncology·2022
Same author

Race, tumor location, and disease progression among low-risk prostate cancer patients.

Cancer medicine·2020

Related Experiment Videos

Vardenafil: efficacy, tolerability and future directions.

Kevin R Rice1, Robert C Dean

  • 1Urology Service, Walter Reed Army Medical Center, Urology Clinic-4F, 6900 Georgia Avenue, NW, Washington, DC 20307, USA. KEVIN.RICE6@US.ARMY.MIL

Expert Opinion on Drug Metabolism & Toxicology
|May 7, 2009
PubMed
Summary

Vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor, effectively treats erectile dysfunction. Emerging research suggests its potential in penile rehabilitation, benign prostatic hyperplasia, and pulmonary hypertension management.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Urology
  • Cardiology

Background:

  • Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor.
  • It is primarily used for treating erectile dysfunction (ED).
  • Its potency and specificity may reduce side effect incidence.

Purpose of the Study:

  • To review the established efficacy of vardenafil in treating ED.
  • To explore emerging therapeutic applications of vardenafil.
  • To highlight vardenafil's potential in penile rehabilitation, lower urinary tract symptoms (LUTS), and pulmonary hypertension (PH).

Main Methods:

  • Literature review of clinical studies on vardenafil.
  • Analysis of efficacy data for ED treatment.
  • Evaluation of preliminary data for off-label indications.

Main Results:

  • Vardenafil demonstrates proven efficacy in treating erectile dysfunction.
  • Studies indicate vardenafil's promise in post-surgical penile rehabilitation.
  • Vardenafil shows potential for alleviating LUTS associated with benign prostatic hyperplasia (BPH).
  • Its role in managing pulmonary hypertension is under investigation.

Conclusions:

  • Vardenafil is a well-established treatment for ED.
  • Further research is warranted to confirm its efficacy in penile rehabilitation, BPH-related LUTS, and PH.
  • Vardenafil may offer a broader therapeutic profile beyond ED treatment.